Medicalook
Medicalook

Anafranil

http://www.medicalook.com
Anafranil

Anafranil review





Anafranil, which is generically prescribed as clomipramine, is commonly used to treat the symptoms of obsessive-compulsive disorder by affecting the chemicals in the brain that become unbalanced. Anafranil is a tricyclic antidepressant. Tricyclic antidepressants have a risk of increasing the likelihood of suicidal thoughts and new patients require very careful monitoring especially in the first 12 weeks of treatment. Sometimes prolonged use of this medication can lead to thoughts of self harm or suicide.

Some serious side effects may occur when starting Anafranil. In the event of a serious side effect or an allergic reaction the patient should immediately seek medical attention. Allergic reactions include facial swelling, swelling of the lips, mouth, tongue, or throat, hives, and difficulty swallowing. Other serious side effects may include symptoms such as chest pain, heaviness in the chest, a feeling as though a heart attack is happening, sudden numbness or weakness which dominates one side of the body, a sudden onset headache that may be accompanied by confusion, and difficulty with speech, vision, balance, or coordination, lightheadedness, fainting, increased urination, pale skin, unusual weakness, fever with confusion, muscle weakness, sweating, or fast and uneven heart rate, pale skin, unexplained bruising, bleeding, or atypical weakness.

Less serious side effects are more common and typically do not require immediate medical attention, although patients should discuss their side effects with the prescribing physician. Often the discomfort of side effects can be reduced to a more tolerable level by reducing the dosage of Anafranil. Common, less serious side effects include nausea, vomiting, constipation, diarrhea, loss of appetite, stomach pain, an unpleasant taste in the mouth, dry mouth, a sense of anxiousness, restlessness, dizziness, or fatigue, an increase in appetite, weight changes, blurry vision, difficulty concentrating, insomnia, vivid dreams or nightmares, increased sweating, or sexual dysfunction.

Anafranil is not appropriate for everyone. To prevent the worsening of other physical conditions, a thorough medical history should be assessed prior to prescribing this medication. Patients with a medical history that includes heart attacks, heart disease, seizures, strokes, bipolar disorder, severe mental illness such as schizophrenia, kidney disease, liver disease, overactive thyroid, adrenal gland tumor, glaucoma, difficulty urinating, or a history of suicidal behavior while taking tricyclic antidepressants may not be able to take Anafranil or may require careful monitoring while on this medication, depending on the severity and the condition. Patients who have taken an MAO inhibitor in the previous 14 days absolutely can not take Anafranil as serious, life threatening interactions may occur.

The American Food and Drug Administration rated Anafranil as a pregnancy risk category C, which means that Anafranil may cause harm or birth defects to an unborn baby. There is potential risk of harm to a nursing baby, as Anafranil may pass through the mother’s breast milk. The prescribing physician should avoid prescribing Anafranil to women who are pregnant or nursing or who might become pregnant. Patients should inform the prescribing physician before coming off of birth control.

It is important to take Anafranil exactly as it has been prescribed by the physician. If the patient misses a dose, the dose should be taken as soon as possible. However, if it is nearing time for the next regular dose, the missed dose ought to be skipped in order to avoid the potential for an overdose. In the event of a suspected overdose of Anafranil, the patient will require immediate emergency medical attention. A patient who has overdosed may experience either an increase or decrease in the ability to urinate, extreme drowsiness, confusion, agitation, swelling, difficulty breathing, uneven heart rate, vomiting, blurry vision, sweating, muscle stiffness, fainting, lightheadedness, blue lips, blue fingernails, seizures, convulsions, coma, or death.

There is a potential for the risk of drug interactions associated with Anafranil, some of which may be life threatening. Patients can not take MAOIs and Tricyclic medications within 14 days of each other. Medications with a known history of drug interactions with Anafranil include heart medications, blood pressure medications, warfarin, heart rhythm medications, anti-psychotic medications, guanethidine, phenytoin, cimetidine, or methylphenidate.

Anafranil has the following structural formula:

Chemical structure of anafranil


• Molecular formula of anafranil is C19H23ClN2
• Molecular weight is 314.852 g/mol
Anafranil available : 50mg capsules

Generic name: Clomipramine

Brand name(s): Chlorimipramine, Clomipramina, Clomipraminum, Hydiphen

  Your Anafranil review